CAH

Cardinal Health, Inc.

$246.45

−$5.09 (2.02%)Oct 27 close

Health CareS&P 500 Compare Technicals

1M 3M 6M 1Y 2Y

CAHSPY

Wall St. Highest PT $295.00 (+19.7%) Wall St. Avg PT $273.47 (+11.0%)

Underwater Drawdown %Max DD -20.4%Current -4.3%

Relative Strength vs SPY+38.3% vs SPYOutperforming

−$11.10 (4.31%)

+$26.74 (12.17%)

+$14.48 (6.24%)

+$41.76 (20.40%)

YTD

+$42.87 (21.06%)

+$84.18 (51.88%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar

Wall Street analyst consensus

Buy

17 analysts · mean score 1.53

1 = Strong Buy · 5 = Sell

Strong Buy318%

Buy1165%

Hold318%

Underperform00%

Sell00%

Wall Street consensus

Analyst price targets

Current price$246.45

Average target$273.47

+$27.02 (+11.0%) upsideaverage target vs current price

CurrentAverageMedian

Low$235.00

Median$276.00

High$295.00

12-month Wall Street target range

Recent analyst rating changes · 30

Reiterated

2026-10-20 · Mizuho reiterated Outperform on CAH

Reiterated

2026-10-16 · UBS reiterated Buy on CAH

Initiated

2026-08-19 · RBC Capital started covering CAH at Outperform

Reiterated

2026-08-13 · TD Cowen reiterated Buy on CAH

Reiterated

2026-08-13 · JP Morgan reiterated Neutral on CAH

Reiterated

2026-08-13 · Barclays reiterated Overweight on CAH

All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$57.1B

P/E (last 12 months)34.1

P/E (next 12 months, estimated)17.5

52-week range$161.64 – $259.21

Revenue growth (latest quarter vs a year ago)+5.8%

Dividend yield0.82%

Analyst consensusBuy (15)

Average analyst price target$273.47 (+11%)

What they do

Cardinal Health, Inc. operates as a healthcare services and products company in the United States and internationally. It operates in two segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. The company offers customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home.

Healthcare · Medical Distribution

Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum

49th percentile in sector

C+

12-1 return: +17.5%
Percentile within its GICS sector across the S&P 1500.

Growth

35th percentile in sector

C-

Revenue growth (YoY): +5.8%
Percentile within its GICS sector across the S&P 1500.

Value

52nd percentile in sector

C+

Forward E/P: 5.5% · EBITDA/EV: 6.6%
Percentile within its GICS sector across the S&P 1500.

Profitability

24th percentile in sector

Profit margin: +0.7% · Return on equity: –
Percentile within its GICS sector across the S&P 1500.

Revisions

Not enough data yet

–

EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth

Outside this model's universe or screens

Momentum Top 15

ranked 58 of 499 · 12-month momentum 51.0%

Momentum Blend

Not in the current book

New Highs Growth

Outside this model's universe or screens

SURVYR. Barbell Momentum & T-Bill Shield

Outside this model's universe or screens

SURVYR. Physical AI Grid & Power

Outside this model's universe or screens

SURVYR. Long Book

Not in the current book

Earnings & events

CAH earningsNext report in 9 days

Next report · quarter Sep 2026

Thu Nov 5, 2026Before the open

EPS consensus$2.94 range $2.88–$3.06

Revenue consensus$66.5B 11 analysts

Last 4 quarters · EPS vs estimate

Aug 11, 2026$2.60est $2.42+7.4%Above estimates

Apr 30, 2026$3.17est $2.79+13.7%Above estimates

Feb 5, 2026$2.63est $2.37+11.2%Above estimates

Oct 30, 2025$2.55est $2.17+17.6%Above estimates

In line = within 1% of the estimate.

EstimateActual (beat)Actual (miss)

Quarterly revenue

Quarter	Revenue	YoY
2026-06-30	$63.7B	+5.8%
2026-03-31	$60.9B	–
2025-12-31	$65.6B	–
2025-09-30	$64.0B	–
2025-06-30	$60.2B	–

Recent dividends

2026-10-01: $0.516 · 2026-07-01: $0.516 · 2026-04-01: $0.511 · 2026-01-02: $0.511 · 2025-10-01: $0.511 · 2025-07-01: $0.511 · 2025-04-01: $0.506 · 2025-01-02: $0.506

News & catalysts

More news

Dow Jones Biotech Giant Amgen Breaks Out Ahead Of Q3 Earnings Results

Investor's Business Daily · 8h ago

Rating changes

Reiterated

2026-10-20 · Mizuho reiterated Outperform on CAH

Reiterated

2026-10-16 · UBS reiterated Buy on CAH

Initiated

2026-08-19 · RBC Capital started covering CAH at Outperform

Reiterated

2026-08-13 · TD Cowen reiterated Buy on CAH

Reiterated

2026-08-13 · JP Morgan reiterated Neutral on CAH

Reiterated

2026-08-13 · Barclays reiterated Overweight on CAH

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades

Hollar Jason M.